IPO Action Brief: Scribe sets $13-$15 terms, but access is not verified
Scribe Therapeutics is the fresh U.S. IPO to watch after setting a $13-$15 range, but no mainstream retail allocation is verified; today's SPAC debuts and the dated Reformation watchlist add context.
Today's Spotlight: Scribe Therapeutics sets terms, but access is not verified
Status: Terms disclosed; not priced; no public mainstream retail allocation verified
Offer range: $13-$15 per share
Expected trade date: July 24, 2026
Minimum buy-in: Not disclosed
Broker access: Not publicly verified
Scribe Therapeutics is a Phase 1 biotechnology company developing in vivo CRISPR therapies for cardiovascular and metabolic diseases. Its lead program, STX-1150, is designed to lower LDL-C by repressing PCSK9 without permanently changing the underlying DNA. 1
The fresh filing is the reason SCTX matters this week. Scribe is offering 7.15 million shares at $13-$15, implying about $100.1 million of gross proceeds at the midpoint. The company says its first-in-human STX-1150 trial in Australia can enroll up to 64 adults, with initial safety, tolerability, and LDL-C data expected in the first half of 2027. 2
The most notable demand signal is strategic, not retail. Eli Lilly has indicated an interest in buying shares that, together with its existing holdings, could equal up to 10.9% of Scribe after the offering and a concurrent private placement. Sanofi's Aventis unit and Genzyme have also agreed to buy about $7.5 million of shares, subject to the IPO closing. The Lilly indication is not binding, so it is a signal rather than a committed anchor order. 1
The key risk: This is still an early clinical story. Preclinical durability and gene-editing results are not human efficacy or safety data. The next material checkpoint is the 2027 trial readout, not the headline $100 million deal size.
For retail investors, the access line is more important than the ticker. The prospectus mentions a directed share program of up to 5% for certain directors, officers, employees, and associated persons. That is not evidence of a general allocation through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. The filing also says no public market currently exists for SCTX. 1
Actionable Now
No U.S. retail IPO allocation window met the channel's verification standard today. The public calendar and filing sources reviewed show pricing and listing events, but no mainstream-broker page with a confirmed ticker, offer terms, minimum buy-in, deadline, and access path. A scheduled debut is not the same thing as a subscription window.
| Offer | Price range | Minimum buy-in | Deadline | Verified brokers |
|---|---|---|---|---|
| None verified | Not applicable | Not applicable | No verified open window | None |
Market Pulse
- B&R Technology Merger Corp. priced a $325 million SPAC. The deal covers 32.5 million units at $10.00, with Nasdaq trading under BRTMU beginning July 21. Each unit includes one Class A ordinary share and one-third of a warrant, with each whole warrant exercisable at $11.50. It is a listing-day event, not a confirmed retail IPO allocation. 3
- Southern Cross Acquisition I Corp. priced $100 million. Its 10 million units are priced at $10.00 and are expected to trade under NCOOU on July 21, with closing expected July 22. Each unit includes an ordinary share, a redeemable warrant, and a right to receive one-fourth of an ordinary share after a business combination. The SPAC has a generalist target search, including possible China-based candidates. 4 5
- The calendar is busy, but access is still the bottleneck. Yahoo's July 21 IPO calendar lists BRTMU, Freenome, and NCOOU among the day's expected events. That confirms market activity, not broker availability or a public subscription right. 6
HK Desk
No Hong Kong public subscription open today or closing within two days was verified from the accessible exchange and public-calendar sources reviewed. The HKEX page available today is a newly listed and traded securities page, not an open-offer timetable with a confirmed price, board lot, application deadline, and listing date. Treat this as a coverage gap, not proof that no offer exists anywhere. 7
| HK public offer | Offer price | Board lot | Deadline | Status |
|---|---|---|---|---|
| None verified | Not confirmed | Not confirmed | Not confirmed | No action |
On The Radar
| Company | Terms or pricing date | Expected listing | Why it matters |
|---|---|---|---|
| Scribe Therapeutics (SCTX) | Terms disclosed July 20; $13-$15 range | July 24 | First-in-human CRISPR program, Eli Lilly interest, and a clear 2027 clinical-data catalyst. 1 2 |
| Reformation (REF) | Terms disclosed July 20; $15-$17 range, about $225 million | July 30 | A recognizable direct-to-consumer apparel brand with more than $500 million of net revenue and a large consumer deal to watch. 8 |
July 21 is a regular U.S. exchange trading day under the NYSE's 2026 holiday calendar. The practical takeaway is narrow: SCTX is the new filing to read for terms, clinical risk, and strategic demand signals; BRTMU and NCOOU are listing watches; and no verified public subscription window is open in the evidence reviewed today. 9
参考ソース
- 1Scribe Therapeutics Form S-1/A
- 2Scribe Therapeutics IPO profile
- 3B&R Technology Merger Corp. pricing release
- 4Southern Cross Acquisition I Corp. pricing release
- 5SPACInsider NCOOU profile
- 6Yahoo Finance IPO calendar for July 21
- 7HKEX Newly Listed Securities
- 8Reformation IPO profile
- 9NYSE Holidays and Trading Hours
関連コンテンツ
- ログインするとコメントできます。
More from this channel
- IPO Action Brief: SCTX prices at $15, but retail access is still unverified
- IPO Action Brief: Scribe heads for pricing, but retail access is still unverified
- IPO Action Brief: Freenome goes public, but no retail subscription window
- IPO Action Brief: Ticketplus reaches debut day, but no retail window
- IPO Action Brief: AMACU prices $250M, but no retail window
- IPO Action Brief: Csquare Prices Below Range, No Retail Window
- IPO action brief: YLUZ files, no retail window yet